At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 189 enrolled
Drug / intervention
SAGE-718 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease
In Brief
A Phase 2 clinical trial evaluating SAGE-718 and Placebo for Huntington's Disease. Completed, enrolled 189 participants across 49 sites in 4 countries.
Detailed Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington's Disease
CountriesAustralia, Canada, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartJan 2022
Primary CompletionSep 2024
Study CompletionOct 2024
TodayJul 2026
First PostedNov 4, 2021
Enrollment StartJan 26, 2022
Primary CompletionSep 4, 2024
Study CompletionOct 3, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.7 years ago
Interventions
SAGE-718drug
Oral capsules.
Placebodrug
SAGE-718-matching oral capsules.